About Us

Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients.


Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009. CTL was rebranded as Celixir in 2016.

Ever since embryonic stem (ES) cells were derived from mice...
To understand the far-reaching effects of the FDA’s approval of...
After 30 years and thanks to extensive stem cell research,...
The potential of the use of stem cells within regenerative...
Florence | 18 to 21 October 2016

Presentation by Celixir :

  • Fixing the So-called Unfixable: Regenerating Untreatable Fixed Myocardial Scar in Heart Failure Patients; A. Reginald, S. Sultan, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis

Celixir Posters :

  • Immunomodulatory Progenitor Cells: A Novel And Safe Allogeneic Therapy For Patients With Ischaemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting; S. Sultan, A. Reginald, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis
  • Tendoncel Phase II Placebo Controlled Randomized Clinical Trial Results For A Novel Allogeneic Regenerative Topical Medicine In Treatment Of Chronic Tendon Injury; A. Reginald, S. Sultan, A. Mousiadou, L. Chapman, M. Evans & G. Panagiotis
“Introduction to cell & gene therapy” and “Topic Based Partnering” Event details here
Germany 17 April 2017
“The differences in culture of institutional biotech investors in Europe versus the US, and how that impacts the ability of...
London 10 May 2017
Organized by World High Technology Society (WHTS), The 11th Annual World Congress of Regenerative Medicine & Stem Cell-2017 was held...
Singapore 16 November 2017
Our Work in Pipeline
PHASE 2 : Our first investigational cardiac regenerative medicine consists...
PHASE 3 : Our investigational topical gel containing platelet lysate is...
CLINICAL TRIAL READY : PML cells are being investigated as...
Find Out More
Our pivotal position in the rapidly evolving regenerative medicine field is supported by a group of leading investors.
Our continued focus on innovation is the key to unlocking the potential of regenerative medicine. We combine the unique expertise of scientists.
We are passionate about advancing ground-breaking regenerative medicines and work towards this goal via collaborative partnerships.
Twitter Feed